1043-47 Evidence for immediate induced percutaneous coronary intervention matrix metalloproteinase 2 variations in peripheral samples to predict target vessel revascularization after nondrug-eluting stent implantation  by Brasselet, Camille et al.
42A ABSTRACTS - Angiography & Interventional Cardiology JACC March 3, 2004
An
gi
og
ra
ph
y 
&
 In
te
rv
en
tio
na
l C
ar
di
ol
og
y
1043-43 The Incremental Hospital Cost of Treating Major 
Complications Among Medicare Beneficiaries 
Undergoing Percutaneous Coronary Interventions
Aaron Kugelmass, David Cohen, Phillip Brown, Michael Mack, Edmund Becker, Steven 
Culler, April Simon, Emory University, Atlanta, GA, Cardiac Data Solutions, Inc., Atlanta, 
GA
Background: Studies of Percutaneous Coronary Intervention (PCI) have focused on
mortality and restenosis. Little is known about the hospital cost of treating acute PCI
complications. We studied the incremental hospital resource consumption (cost and
length of stay (LOS)) due to acute PCI complications.
Methods: A retrospective analysis was conducted using the Medicare Provider Analysis
and Review (MedPar) Files from 2002. This consists of 313,517 admissions whose pri-
mary procedure was PCI. Procedures, complications, and comorbidities were identified
using ICD-9 codes. Hospital costs were estimated from billed charges using the hospi-
tal’s cost-to charge ratio. Multivariate regression analysis was used to estimate the incre-
mental hospital resources associated with complications, after controlling for age,
gender, and 26 comorbiditites.
Results: Complications of PCI procedures occur in less than 3.3% of admissions. The
hospital cost (unadjusted for morbidities) of PCI with at least one major complication was
$29,440 (mean LOS of 9.4 days) compared to $14,046 (mean LOS 2.9 days) for those
without a complication. The table reports estimated incremental cost and LOS after con-
trol for age, gender, and comorbidities.
Conclusion: This retrospective study of Medicare beneficiaries indicates that complica-
tions significantly increase cost. Quality improvement efforts to reduce complications,
could not only result in improved patient outcomes, but could also prove to be cost-effec-
tive.
1043-44 Identifying Patients at Risk for Ischemia-Driven Target 
Vessel Revascularization After Primary Percutaneous 
Coronary Intervention: Lessons From the Primary 
Angioplasty in Myocardial Infarction (PAMI) Trials
Rajendra H. Mehta, Kishore J. Harjai, Judy Boura, William O'Neill, Cindy L. Grines, On 
Behalf of Primary Angioplasty in Myocardial Infarction (PAMI) Investigators, University of 
Michigan, Ann Arbor, MI, William Beaumont Hospital, Royal Oak, MI
Background: Patients (pts) undergoing primary percutaneous coronary intervention
(PCI) may require target vessel revascularization for recurrent ischemic event. However,
there is no data regarding pts at risk for ischemia-driven target vessel revascularization
(ITVR).
Methods: We examined 2981 pts with ST elevation myocardial infarction enrolled in vari-
ous PAMI trials, who underwent primary PCI. Univariate testing followed by multivariate
logistic regression analysis was performed to determine pt characteristics that identified
those at risk for ITVR.
Results: Of 2981 pts undergoing primary PCI, ITVR was required in 321 pts (11%) at
six-months. A third of ITVR (107/321) were required before hospital discharge. Com-
pared to the cohort without ITVR, pts requiring ITVR were younger (61+12 vs. 59+12,
p=0.036), females (26% vs. 32%, p=0.018), more likely to have systolic blood pressure
>100 mmHg on presentation (67% vs. 74%, p=0.022), Killip Class I on presentation (87%
vs. 91%, p=0.05), family history of coronary artery disease (36% vs. 42%, p=0.035), and
higher post-procedure dissection (15% vs. 23%, p=0.001) and in-hospital (1% vs. 10%,
p<0.001) and six-month (2% vs. 19%) reinfarction. In contrast, left circumflex as infarct
artery (15% vs. 10%, p=0.022), and the use of ticlopidine (78% vs. 72%, p=0.044) and
stents (41% vs. 35%, p=0.057) were less frequent among pts requiring ITVR. Multivariate
analysis identified age (for each 10 years increment, odds ratio [OR], 0.85; 95% confi-
dence interval [CI], 0.76-0.94; p=0.003), female gender (OR 1.41, 95% CI, 1.05-1.89;
p=0.022), and final dissection (OR 1.69, 95% CI, 1.23-2.33, p=0.001) as independent
risk factors for ITVR (c statistic 0.57, DF 8, p=0.14). In-hospital and six-month mortality
were similar in the 2 groups while length of stay was longer in the pts requiring ITVR
(median 6.3+5.4 vs. 7.3+5.7 days, p<0.001).
Conclusions: Our study identifies the incidence, risk factors and outcomes for pts who
require ITVR after primary PCI. Importantly, our data suggests that no increase in
adverse events occurs, if ITVR is promptly performed to treat recurrent ischemia in
patients undergoing primary PCI.
1043-45 Preprocedural Statin Administration and Incidence of 
Creatine-Kinase and Troponin I Elevation After Elective 
Percutaneous Coronary Stent Implantation
Carlo Briguori, Antonio Colombo, Amelia Focaccio, Anna Violante, Pasquale Balestrieri, 
Bruno Golia, Pierfranco Scarpato, Pietro Paolo Elia, Stefano Lepore, Mariateresa 
Librera, Flavio Airoldi, Bruno Ricciardelli, Laboratory of Interventional Cardiology, Clinica 
Mediterranea, Naples, Italy, Laboratory of Interventional Cardiology, San Raffaele 
Hospital, Milan, Italy
Background: Myocardial injury after percutaneous coronary interventions (PCI) has
been recognized as a prognostically important event. Hermann et al. recently found in a
retrospective, non-randomized study that preprocedural statin therapy seems to be asso-
ciated with a reduction in the incidence of larger-sized, stenting-related myocardial infarc-
tions. Thus, we performed a prospective, randomized study to test this finding.
Methods: 470 patients scheduled for elective de novo PCI with stent implantation, not on
statins at the time of our observation, were randomly assigned to a pre-procedural (< 7
days before PCI) statin administration (Statin Group; n = 236) or to the Control Group (n
= 224). Incidence of periprocedural myocardial injury was assessed by analysis of creat-
ine kinase (CK-MB; upper limit of normal [ULN] 3.5 ng/mL) and cardiac troponin I (cTnI;
threshold 0.10 ng/mL) before 6, and 12, hours after the intervention.
Results. 34 patients (20 Statin group and 14 Control group) were missed because of
lack of CK-MB and/or cTnI data. The 2 groups were well matched for the most relevant
clinical, angiographic and procedural characteristics. IIbIIIa inhibitors were electively
administered in 57% of patients in the Control Group and 52% in the Statin Group (p=
0.31). Anatomic complication potentially responsible for myocardial injury (i.e. side
branch occlusion or compromise, prolonged slow-no flow) occurred in 7.5% in the Statin
Group versus 4.4% in the Control Group (p = 0.18). CK-MB peak was 5.5 ±13.3 ng/mL in
the Statin Group and 7.0 ±14.7 ng/mL in the Control Group (p = 0.026). cTnI peak was
0.85 ± 2.54 ng/mL in the Statin Group and 1.21 ± 2.61 in the Control Group (p = 0.029).
The incidence of CK-MB elevation >5x ULN was 5.4% in the Statin Group versus 11.7%
in the Control Group (OR = 0.43; 95% CI = 0.21-0.88; p = 0.025). The incidence of cTnI
elevation >5x was 21.2% in the Statin Group versus 31.3% in the Control Group (OR =
0.59; 95% CI = 0.38-0.90; p = 0.017).
Conclusions: This randomized study supports the findings that preprocedural statin
therapy is associated with a reduction in the incidence of periprocedural myocardial
injury.
1043-46 Vulnerable Plaque Can Be the Predominant Source of 
Serum Interleukin-6 but Not of Serum C-Reactive 
Protein in Patients With Acute Myocardial Infarction
Shuichiro Higo, Shinsuke Nanto, Masaaki Uematsu, Tomoki Ohara, Takakazu Morozumi, 
Jun-ichi Kotani, Masaaki Awata, Toshinari Onishi, Osamu Iida, Noriaki Ito, Seiki Nagata, 
Kansai Rosai Hospital, Amagasaki, Japan
Background: Although serum levels of interleukin (IL)-6 and C-reactive protein (CRP)
are elevated in patients with acute coronary syndrome, the origins of these inflammatory
markers remain uncertain.
Methods: We analyzed 19 patients with acute myocardial infarction who underwent
emergent percutaneous coronary intervention (PCI) using thrombus aspiration and distal
protection by PercuSurgeTM GuardWire system, which enabled intracoronary blood sam-
plings. Initial intracoronary aspiration, subsequent balloon angioplasty and/or stenting
under distal protection, and second aspiration were completed in all patients. Blood sam-
ples were obtained from the femoral artery (FA), the coronary artery before (Initial) and
after the balloon dilation of the culprit lesion under distal protection (Second). Serum lev-
els of IL-6 and high sensitive (hs)-CRP were measured.
Results: Shown in the table. Serum levels of IL-6 significantly increased after PCI (Sec-
ond), while hs-CRP remained unchanged throughout the procedure. Serum CRP levels
one day after the PCI markedly increased over any other samples (1.27±0.38 mg/dl,
p<0.0001). Thus, the mechanical disruption of the culprit lesion by PCI induced the ele-
vation of serum IL-6 levels, but had no influence on serum CRP levels.
Conclusion: Vulnerable plaque in patients with acute myocardial infarction can be the
predominant source of serum IL-6 but not of serum CRP.
1043-47 Evidence for Immediate Induced Percutaneous 
Coronary Intervention Matrix Metalloproteinase 2 
Variations in Peripheral Samples to Predict Target 
Vessel Revascularization After Nondrug-Eluting Stent 
Implantation
Camille Brasselet, Sophie Pérotin, Roselyne Garnotel, Antoine Lafont, Marie Métivier, 
Jacques Elaerts, Philippe Gillery, Damien Metz, CHU Robert Debre, Reims, France, 
American Memorial Hospital, Reims, France
Background and objectives:
Matrix metalloproteinases (MMPs) and inhibitors (TIMPs) play a pivotal role in healing
process by controlling the turn-over of the extracellular matrix. Recent studies have men-
tioned an increase of MMP after percutaneous coronary intervention (PCI), assessed in
the coronary sinus circulation, and its correlation with long term late loss. In search for
practical application, we investigated changes in the expression of MMPs and TIMPs
after PCI, through conventional sampling.
Material and Methods:
Adjusted Incremental Hospital Cost and LOS by Complication
Complication Incremental Cost Length of Stay (days)
Death $3,351 -0.9
Septicemia $21,610 9.1
Post-Operative Stroke $4,673 2.9
Acute Renal Failure $11,600 5.8
Vascular Complication $4,546 2.4
ARDS $15,667 4.6
CABG Surgery $25,388 4.9
FA Initial Second p value
IL-6 (pg/ml) 8.7±2.2 10.4±2.4 13.2±3.9* * p<0.01 vs FA
hs-CRP (mg/dl) 0.19±0.07 0.17±0.06 0.17±0.05 N.S.
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In a monocentric and prospective study involving 96 consecutive patients (stable angina:
28; unstable angina: 30 and recent myocardial infarction: 38) referred to PCI revasculari-
sation, we determined the concentrations of serum MMP 2-9 and TIMP 1-2. Each patient
was treated with one or more non-drug eluting stent, with or without balloon-predilatation.
Blood was sampled from aorta before and immediately post-PCI and from venous access
24 hours later (J1). MMPs plasma concentrations were measured by enzyme-linked
immunoabsorbent assay. Follow-up (15.4 ± 3.2 months) documented the occurrence of
reintervention, myocardial infarction (MI) and death. Value are expressed as mean ±
SEM.
Results:
About MMP2 plasma level, there was a trend to higher values after PCI followed by a
decrease at J1. Those variations did not reached the significant level. By contrast,
MMP9, TIMP 2-9 were significantly lower after PCI then increased significantly at J1, for
the whole population and the3 different subgroup of clinical status. Despite non signifi-
cant variation for the whole population and subgroups, post-PCI MMP2 plasma level cor-
related with reintervention (p: 0.0003). Furthermore, a positive variation of MMP2
between pre and post-PCI (p: 0.0003) as well as a negative variation of MMP 2 between
post-PCI and J1 (p: 0.0009) correlated both with reintervention.
Conclusions:
Variations of MMPs and inhibitors immediately after PCI can be documented through
conventional vessel access. MMP2 kinetic after stent implantation allows interesting
information regarding the risk of reintervention.
1043-48 Impact of Cerebrovascular and Peripheral Arterial 
Disease on Outcomes After Percutaneous Coronary 
Interventions
Eugenia Nikolsky, Roxana Mehran, George D. Dangas, Gary S. Mintz, Zoran Lasic, Tudor 
Vagaonescu, Ramona Pop, Alexandra J. Lansky, Issam Moussa, Lynn Glasser, Sharif 
Ibrahim, Iyer Sriram, Martin B. Leon, The Cardiovascular Research Foundation and the 
Lenox Hill Heart and Vascular Institute, New York, NY
Background. Cerebrovascular and peripheral arterial diseases frequently coexist in pts
with coronary artery disease (CAD).Whether the presence of cerebrovascular disease
(CVD) alone or in combination with peripheral arterial disease (PAD) influences the out-
comes of percutaneous coronary intervention (PCI) is not known. We compared the
impact of symptomatic CVD and/or PAD on the prognosis of pts undergoing PCI. Meth-
ods and Results. Of 10,428 pts, symptomatic CVD, PAD, or both were identified in 743
(7.1%), 1,541 (14.8%) and 424 (4.1%) pts, respectively. Compared to the remaining
7,720 pts without these conditions (controls), pts with CVD, PAD, or both were older,
more frequently female, and had lower ejection fraction. Pts with CVD, PAD, or both had
higher than controls rates of in-hospital mortality (2.8%, 2.0%, and 2.4%, respectively, vs
0.9%, P<0.0001), stroke (0.8%, 0.5%, and 1.2% vs 0.2%, P=0.0015), and limb ischemia
(1.6%, 3.0%, and 3.1% vs 0.6%, P<0.0001). One-year outcomes were significantly worse
in pts with CVD, PAD, or both than in controls (Table). By multivariate analysis, CVD was
an independent predictor of in-hospital mortality (odds ratio=2.29, P=0.0031). One-year
mortality was predicted by either CVD (odds ratio=1.44, P=0.02) or PAD (odds
ratio=1.76, P<0.0001); but the two were not additive. Conclusions: Symptomatic CVD
and/or PAD are associated with adverse in-hospital and 1-year outcomes and indepen-
dently predict in-hospital and/or 1-year mortality.
1043-49 Current Percutaneous Transluminal Coronary 
Angioplasty Practice and Clinical Outcomes in the 
Netherlands: The Real World
Pascalle S. Monraats, Willem R.P Agema, Aeilko H. Zwinderman, Robbert J. de Winter, 
Rene A. Tio, Pieter A.F.M Doevendans, Harry J.G.M Crijns, Moniek P.M de Maat, Douwe 
E. Atsma, Arnoud van der Laarse, Ernst E. van der Wall, J.Wouter Jukema, Leiden 
University Medical Center, Leiden, The Netherlands
Background: Percutaneous transluminal coronary angioplasty (PTCA) is limited by the
recurrence of luminal stenosis. This study evaluated the incidence and risk factors of clin-
ical restenosis in an unselected patient population with contemporary intervention tech-
niques in the pre-Drug Eluting Stent (DES) era.
Methods: The GEnetic DEterminants of Restenosis (GENDER) project was a multi-
center prospective cohort study, which included 3,146 patients after successful PTCA.
Patients with acute myocardial infarction (MI) were excluded.
Results: A total of 3,146 patients (age 62.1±10.7 yrs) were followed for 10±3 months. Of
the patients 2,250 (71.5%) were male, 459 (14.6%) had diabetes and 1,459 (46.4%) had
multivessel disease. The majority was treated for stable angina. Stenting was performed
in 2,340 (74.4%) patients and IIb/IIIa inhibitors were used in 820 (26.1%) patients. Target
vessel revascularization after the first month by either CABG or PTCA was necessary in
304 patients (9.7%). Thirty-three (1.1%) died of cardiac disease and 22 (0.7%) suffered
from MI attributable to the originally treated vessel. Overall a need for revascularization,
cardiac death or MI occurred in 346 patients (11.0%). After correction for all baseline
characteristics in a multivariate analysis; diabetes, hypertension, peripheral vessel dis-
ease, multivessel disease and treatment of type C lesions prevailed as independent risk
factors for clinical restenosis. After dividing the patients into subgroups depending upon
the number of risk factors present in these patients, we constructed six subgroups. Group
one had zero or one risk factor (n=700) and a clinical restenosis rate of 7.6%, whereas
group three, with four or five risk factors (n=386) had a rate of 17.3% after one year fol-
low-up.
Conclusion: In this unselected series of patients clinical restenosis occurred in only
11.0%. Proper selection of patients that benefit from new devices is warranted, since the
vast majority is well treated with standard techniques. Although patients with more clini-
cal risk factors show a higher restenosis rate, it remains difficult to predict events.
Genetic determinants may have additional value for stratifying patients at risk.
1043-50 The Extent of Coronary Atherosclerosis Determined by 
Angioscopy Is a Risk Factor of Restenosis
Yasunori Ueda, Isamu Mizote, Tomohito Ohtani, Masaya Usami, Takashi Oka, Astushi 
Hirayama, Kazuhisa Kodama, Osaka Police Hospital, Osaka, Japan
Background: Although the development in the techniques and devices for PCI has
reduced the restenosis rate, restenosis has not been completely prevented and its risk
factors have not been thoroughly clarified. Progression of atherosclerosis is known to
increase the inflammation and thrombus formation, which may promote restenosis.
Therefore, we tested if angioscopically determined extent of atherosclerosis could be a
risk factor of restenosis.
Methods: Among 1050 patients of ischemic heart disease who received PCI, angioscopic
evaluation of coronary atherosclerosis was performed in 263 patients. Target vessel was
observed by angioscopy and the color of plaques was graded as 0 (white), 1 (slight yel-
low), 2 (yellow), or 3 (intensive yellow). The extent of atherosclerosis was assessed by
the number of yellow plaques (N), maximum (MC) and sum (SC) of color grade of
observed plaques. The rate of target vessel revascularization (TVR) was used as the
marker of restenosis.
Results: TVR of all 1050 patients was 19%, and of all 263 patients who received angio-
scopic examination was 16%. TVR increased according to the increase in N (N3, 29%),
MC (MC=1, 10%; MC=2, 16%; MC=3, 23%), and SC (SC<3, 16%; SC>3, 23%; SC>5,
25%; SC>7, 27%; SC>9, 29%). Repeat TVR also increased according to the increase in
N (N=0/1, 0%; N=2, 9%; N>3, 21%), MC (MC=0/1, 0%; MC=2, 11%; MC=3, 29%), and
SC (SC=0/1, 0%; SC=2/3, 6%; SC>4, 24%).
Conclusions: Angioscopically determined extent of coronary atherosclerosis according to
the number of yellow plaques and the yellow color intensity of plaques is a risk factor of
restenosis.
1043-63 Elevated Peak Rather Than Admission White Blood Cell 
Count Is Associated With Adverse Cardiovascular 
Outcome in Patients Undergoing Percutaneous 
Coronary Intervention for Acute Myocardial Infarction
Ahmed S. Ahmed, Mohammed Murtaza, Almutaz Kartoumah, Christopher Bartalos, 
Ambareesh Bajpai, Jennifer Jean Marcellus, Tarek Kteleh, Rasha Mohamed, Daniel 
Noonan, James Boyd Sterner, Timothy Catchings, Richard Webel, Greg C. Flaker, 
University of Missouri-Columbia, Columbia, MO
Background:
The role of inflammation in acute coronary syndrome is well established. Recent studies
suggest that elevated admission white blood cell count (WBC) is associated with adverse
outcomes in patients undergoing PCI for acute myocardial infarction (AMI).
Hypothesis:
Peak rather than admission WBC in patients undergoing PCI for AMI is a better marker of
the magnitude of inflammation and thus more accurately predicts adverse long term out-
come.
Methods:
Prospectively collected data on consecutive patients undergoing PCI for AMI was
obtained from the American College of Cardiology-National Cardiovascular Data Regis-
try. Patients were divided into 5 strata based on WBC. Three years follow up data for
major adverse cardiac events was analyzed.
Results:
There were 496 patients including 260/496 (52.42%) patients with ST elevation AMI and
236/496 (47.58%) patients with non ST elevation AMI. The peak WBC ranged from 3.8 to
44.9 X109/L. The admission WBC ranged from 2.4 to 31.6 X109/L. Baseline characteris-
tics including age, gender and cardiac risk factors were not significantly different among
groups. High peak WBC was associated with higher mortality (p <0.0001) while elevated
admission WBC failed to show statistically significant relationship to outcome.
Conclusion:
WBC count, a readily available inflammatory marker is useful in stratifying low Vs high-
risk patients with AMI undergoing PCI.
Elevated peak WBC count could select patients for more aggressive therapeutic strate-
gies. 
One-Year Outcomes
Endpoint, % (+)CVD
(-)PAD
N=743
(-)CVD
(+)PAD
N=1541
(+)CVD
(+)PAD
N=424
(-)CVD
(-)PAD
N=7720
P-value*
Death 9.9 12.6 16.7 4.7 <0.0001
Q-wave MI 1.5 1.0 2.3 1.2 0.19
Non-Q wave MI 6.6 6.3 9.4 5.2 0.004
TVR 21.5 25.0 23.1 21.2 0.02
*Chi-square statistics
